XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection. (2022)
Attributed to:
MRC Transition Support CSF Nicholas Matheson
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-34339-w
PubMed Identifier: 36385143
Publication URI: http://europepmc.org/abstract/MED/36385143
Type: Journal Article/Review
Volume: 13
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723